STOCK TITAN

Activist Blockholder Reveals 27.3% of STAAR, Vows to Vote Against Alcon Deal

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Broadwood Partners, Broadwood Capital and Neal C. Bradsher disclose a combined stake in STAAR SURGICAL CO equal to 27.3% of the outstanding common stock. The filing states Broadwood Partners beneficially owns 13,519,491 shares and Mr. Bradsher beneficially owns 13,545,391 shares based on 49,553,035 shares outstanding. The Reporting Persons say they intend to vote against the definitive merger agreement under which Alcon would acquire STAAR and have issued a related press release. They also state they are exploring strategic alternatives, including contacting potential strategic and financial partners, and reserve the right to change their holdings or take other actions depending on market and deal developments.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A 27.3% block stake and explicit opposition to the Alcon merger is material and could alter transaction dynamics.

The Reporting Persons hold a significant minority position representing 27.3% of STAAR's shares and have publicly declared intent to vote against the proposed Alcon transaction. That holding size gives them substantial influence over shareholder vote outcomes and negotiating leverage. Their stated exploration of alternatives indicates potential for solicitation of rival bids or proxy activity. There are no disclosed plans to propose specific corporate actions today, but the combination of sizable ownership and active engagement is a material development for investors and transaction counterparties.

TL;DR: Broadwood's stance introduces a credible obstacle to closing the announced Alcon merger and may prompt deal re-evaluation.

With shared voting power over 13,519,491 shares and Mr. Bradsher holding a small portion of sole voting power, Broadwood's opposition is likely to be factored into Alcon's closing calculus. The filing confirms outreach to potential alternative strategic and financial partners, signaling a possible campaign to seek a superior proposal or enhanced terms. The filing does not detail any definitive alternative proposal or litigation strategy, so the near-term outcome remains uncertain.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Broadwood Partners, L.P.
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher / President of Broadwood Capital, Inc.
Date:09/02/2025
Broadwood Capital, Inc.
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher / President
Date:09/02/2025
Neal C. Bradsher
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher
Date:09/02/2025
Comments accompanying signature:
* This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

FAQ

What stake does Broadwood report in STAAR Surgical (STAA)?

The Reporting Persons disclose beneficial ownership of 13,519,491 shares (27.3%) for Broadwood Partners and 13,545,391 shares (27.3%) for Neal C. Bradsher, based on 49,553,035 shares outstanding.

Will Broadwood vote for the Alcon merger with STAAR (STAA)?

No. The filing states the Reporting Persons intend to vote against the definitive merger agreement under which Alcon would acquire STAAR.

Are Broadwood planning any alternative transactions for STAAR (STAA)?

They are exploring strategic alternatives and contacting potential strategic and financial partners, but no definitive alternative proposal is disclosed.

Did Broadwood use borrowed funds to acquire the STAAR shares?

No. The filing states the shares were purchased using working capital and personal funds, with no borrowed funds used other than routine working capital borrowings.

Have there been recent transactions in STAAR shares by Broadwood?

The filing states there have been no transactions in the shares by the Reporting Persons during the past sixty days.
Staar Surg

NASDAQ:STAA

STAA Rankings

STAA Latest News

STAA Latest SEC Filings

STAA Stock Data

1.04B
49.48M
0.56%
111.03%
8.06%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
MONROVIA